Lantern Pharma Inc. (LTRN)

NASDAQ: LTRN · IEX Real-Time Price · USD
9.78
-0.25 (-2.49%)
At close: Mar 27, 2024, 4:00 PM
9.52
-0.26 (-2.66%)
Pre-market: Mar 28, 2024, 4:34 AM EDT

Company Description

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process.

It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors.

The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.

In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways.

Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.

Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data.

The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma Inc.
Lantern Pharma logo
Country United States
IPO Date Jun 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 21
CEO Panna Sharma PH.D.

Contact Details

Address:
1920 Mckinney Avenue, 7th Floor
Dallas, Texas 75201
United States
Phone 972-277-1136
Website lanternpharma.com

Stock Details

Ticker Symbol LTRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001763950
CUSIP Number 51654W101
ISIN Number US51654W1018
Employer ID 46-3973463
SIC Code 2834

Key Executives

Name Position
Panna Sharma President, Chief Executive Officer and Director
David R. Margrave Chief Financial Officer and Secretary
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer and Scientific Consultant
Nicole Leber Investor Relations Associate, Finance and Administrative Coordinator
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder and Advisor
Ernest Kitt B.S., M.S Head of Clinical Operations

Latest SEC Filings

Date Type Title
Mar 18, 2024 10-K Annual Report
Mar 18, 2024 8-K Current Report
Mar 1, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 28, 2024 144 Filing
Feb 28, 2024 144 Filing
Feb 28, 2024 144 Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 29, 2023 8-K Current Report
Dec 1, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 24, 2023 8-K Current Report